The Jain Foundation

The Jain Foundation

The Jain Foundation was established in 2003 by Naseem Jain, using capital from his family's ownership of the Jain Group, an Indian conglomerate with interests in textiles, real estate, and infrastructure. The foundation operates as a nonprofit charitable organization, separate from the family's commercial holdings. Its grant-making is focused on rare diseases and underserved educational needs. The foundation's primary investment posture is in medical research, funding academic institutions and hospitals to advance treatments for dysferlin-deficient LGMD2B. It has awarded over $10 million in grants since inception (per public records). Education grants support K-12 STEM programs in underserved communities, with regional ties to Ohio, Washington, and Indiana. The foundation does not maintain a public investment portfolio or report AUM, as its activities are purely philanthropic. Headquartered across Columbus, Cincinnati, and Seattle, the foundation employs a small team overseen by President Priya Jain. It has not disclosed assets under management or total grants beyond periodic IRS Form 990 filings. A 2024 grant of $500,000 was made to the University of Washington for LGMD research (per the UW news office). No known affiliations with venture philanthropy or impact investing vehicles. The structural differentiator is its singular focus on one rare disease—LGMD2B—which is unusual for a family foundation of its scale. This narrow mandate allows deep specialization in dysferlin biology, but limits broader philanthropic reach. Succession is governed by the Jain family, with no public spinout or planned divestment of the founding wealth.